Tyck till om SwePub Sök här!
onr:"swepub:oai:DiVA.org:uu-462231"
Sökning: onr:"swepub:oai:DiVA.org:uu-462231" > hENT1 Predicts Bene...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
-
- Aughton, Karen (författare)
- Univ Liverpool, Liverpool Expt Canc Med Ctr, 2nd Floor Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.
-
- Elander, Nils (författare)
- Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Univ Liverpool, Liverpool Expt Canc Med Ctr, 2nd Floor Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.;Linköping Univ, Dept Oncol, SE-58183 Linköping, Sweden.
-
- Evans, Anthony (författare)
- Univ Liverpool, Liverpool Expt Canc Med Ctr, 2nd Floor Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.
- visa fler...
- visa färre...
- Univ Liverpool, Liverpool Expt Canc Med Ctr, 2nd Floor Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England Avdelningen för kirurgi, ortopedi och onkologi (creator_code:org_t)
- 2021-11-17
- 2021
- Engelska.
- Ingår i: Cancers. - : MDPI. - 2072-6694. ; 13:22
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase (CDA), inside or outside of the cancer cell, will deaminate gemcitabine, altering transporter affinity. ESPAC-3(v2) was a pancreatic cancer trial comparing adjuvant gemcitabine and 5-FU. Tissue microarray sections underwent in situ hybridization and immunohistochemistry. Analysis of both CDA and hENT1 was possible with 277 patients. The transcript did not correlate with protein levels for either marker. High hENT1 protein was prognostic with gemcitabine; median overall survival was 26.0 v 16.8 months (p = 0.006). Low CDA transcript was prognostic regardless of arm; 24.8 v 21.2 months with gemcitabine (p = 0.02) and 26.4 v 14.6 months with 5-FU (p = 0.02). Patients with low hENT1 protein did better with 5-FU, but only if the CDA transcript was low (median survival of 5-FU v gemcitabine; 29.3 v 18.3 months, compared with 14.2 v 14.6 with high CDA). CDA mRNA is an independent prognostic biomarker. When added to hENT1 protein status, it may also provide treatment-specific predictive information and, within the frame of a personalized treatment strategy, guide to either gemcitabine or 5FU for the individual patient.Simple Summary:Recent clinical trials suggest that combination therapies that include either gemcitabine or 5-fluorouracil (5-FU) both give significant survival benefits for pancreatic cancer patients. The tumor level of the nucleoside transporter hENT1 is prognostic in patients treated with adjuvant gemcitabine but not adjuvant 5-FU. This work shows for the first time that hENT1 is only predictive of benefit from gemcitabine over 5-FU in patients with low levels of CDA transcript. A choice between adjuvant 5-FU based combination therapies (such as FOLFIRINOX) and gemcitabine-based therapy (e.g., GemCap) could be made based on a combination of hENT1 protein and CDA mRNA measured in a resected tumor.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- 5-fluorouracil
- gemcitabine
- pyrimidine
- biomarker
- predictive marker
- prognostic marker
- chemotherapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Aughton, Karen
- Elander, Nils
- Evans, Anthony
- Jackson, Richard
- Campbell, Fiona
- Costello, Eithne
- visa fler...
- Halloran, Christ ...
- Mackey, John R.
- Scarfe, Andrew G ...
- Valle, Juan W.
- Carter, Ross
- Cunningham, Davi ...
- Tebbutt, Niall C ...
- Goldstein, David
- Shannon, Jennife ...
- Glimelius, Bengt
- Hackert, Thilo
- Charnley, Richar ...
- Anthoney, Alan
- Lerch, Markus M.
- Mayerle, Julia
- Palmer, Daniel H ...
- Büchler, Markus ...
- Ghaneh, Paula
- Neoptolemos, Joh ...
- Greenhalf, Willi ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Cancers
- Av lärosätet
- Uppsala universitet
- Linköpings universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
